To mark International Rare Disease Day, the BIA is shining a light on the challenges involved in developing drugs for rare diseases.
There are around 7,000 known rare diseases yet only 5% of these have a single licensed treatment. Though the development journey is often fraught with challenges, the life-changing benefits these treatments can provide to patients and their families make the development of treatments for rare diseases hugely worthwhile. Industry remains committed to developing medicines across a breadth of disease area.
To learn more about the BIA's Rare Disease Industry Group
(RDIG), visit www.bioindustry.org/rdig
***
Sources used:
NORD, Rare Disease Day: Frequently Asked Questions, 2019. Available online via: [ Ссылка ]
Cancer Research UK, How long a new drug takes to go through clinical trials. Available online via: [ Ссылка ]
Seyhan, A., Lost in translation: the valley of death across preclinical and clinical divide, 2019. Available online via: [ Ссылка ]
Thomas, K., The price of health: the cost of developing new medicines, 2016. Available online via: [ Ссылка ]
DiMasi, J., Grabowski, H. and Hansen, R., Innovation in the pharmaceutical industry: New estimates of R&D costs, 2016. Available online via: [ Ссылка ]
